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Abstract
Background: Right ventricular dilatation in the setting of acute pulmonary embolism is associated with an adverse
prognosis. Treatment with a pulmonary vasodilator has never been studied systematically. We evaluated the effect
of epoprostenol on right ventricular diameter and function in patients with acute pulmonary embolism and right
ventricular dilatation.
Methods: In a randomized, single-blind study, 14 patients with acute pulmonary embolism received epoprostenol
or placebo infusion for 24 hours on top of conventional treatment. Effects on right ventricular end-diastolic
diameter, systolic pulmonary artery pressure, right ventricle fractional area changeand tricuspid annular plane
systolic excursion were assessed by serial echocardiography. Furthermore Troponin T and NT-proBNP were
measured serially.
Results: Compared to placebo, epoprostenol was associated with a relative change from baseline in right
ventricular end-diastolic diameter of +2% after 2.5 hours and -8% after 24 hours. Epoprostenol did not have a
significant effect on systolic pulmonary artery pressure, right ventricular fractional area change and tricuspid
annular plane systolic excursion, nor on biochemical parameters.
Conclusion: In patients with acute pulmonary embolism and right ventricular overload, treatment with
epoprostenol did not improve right ventricular dilatation or any other measured variables of right ventricular
overload.
Trial Registration: Registration: URL: NCT01014156
Medical ethical committee: Medisch-ethische toetsingscommissie (METc) from the VUmc (free university medical
centre)
Background
Pulmonary embolism is a frequent and potentially fatal
disorder. Despite immediate treatment with anticoagu-
lants, morbidity and mortality are still high when hemo-
dynamically stable patients with pulmonary embolism
have echocardiographic signs of acute right ventricular
overload [1-3].
An acute increase in right ventricular afterload is the
hallmark of severe pulmonary embolism, and is respon-
sible for many of its clinical manifestations and comp-
lications. The traditional view is that mechanical
obstruction by thrombus mass causes pulmonary hyper-
tension. Therefore, treatment focusses on relieving
mechanical obstruction, either by anticoagulation if
patients are stable, or by thrombolytic therapy in case of
hemodynamic instability [4]. The optimal treatment for
haemodynamically stable patients with signs of right
ventricular overload is unclear. Despite one clinical trial
showing some benefit of thrombolysis in normotensive
patients with pulmonary embolism and echocardio-
graphic signs of right ventricular dysfunction [5], throm-
bolytic therapy continues to be highly controversial in
this patient category [6-8].
Apart from mechanical obstruction, vasoconstriction
of the pulmonary vasculature plays a pivotal role in the
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any medium, provided the original work is properly cited.acute rise in pulmonary artery pressure in patients with
pulmonary embolism [9]. This is supported by the
marked discrepancy between hemodynamic manifesta-
tions of acute pulmonary embolism and the degree of
mechanical obstruction [10]. Furthermore, bringing
about a strictly mechanical obstruction in a pulmonary
artery causes only a modest rise in pulmonary artery
pressure (PAP), rarely resulting in right-sided heart fail-
ure, whereas pulmonary embolism with obstruction of
only 25% of the pulmonary vascular tree can cause
marked acute pulmonary hypertension [11]. Finally, stu-
dies in experimental animal models support a crucial
role for pulmonary vasoconstriction in acute pulmonary
embolism [12,13].
Given the role of pulmonary vasoconstriction in the
pathogenesis of pulmonary embolism-associated pul-
monary hypertension, the potential benefit of pulmonary
vasodilators is important. There is experimental evi-
dence suggesting that antagonising pulmonary vasocon-
striction by administration of selective vasodilators is
beneficial. In animal models of acute pulmonary embo-
lism prostacyclin, a relatively selective pulmonary vaso-
dilator, prevented or partially reversed the rise in
pulmonary vascular resistance and pressure [14,15]. Pre-
treatment with a prostacyclin analogue protected mice
from pulmonary embolism-related death in a dose-
dependent manner [16]. In humans, a case report sug-
gested that inhaled prostacyclin may also be beneficial
for acute pulmonary hypertension associated with pul-
monary embolism [17]. However, the potentially benefi-
cial role of pulmonary vasodilatory therapy in acute
pulmonary embolism has never been studied in a sys-
tematic way.
In this randomized, controlled trial, we evaluated the
effects of epoprostenol, the pharmacological form of
prostacyclin, on echocardiographic abnormalities, car-
diac biomarkers and on hemodynamic and respiratory
symptoms in patients with pulmonary embolism with
echocardiographic signs of right ventricular overload.
Methods
Subjects
A total 82 patients with acute pulmonary embolism, as
diagnosed by spiral CT, were screened for eligibility.
Patients were potentially eligible if they had a recent
(<24 hours) onset or progression of symptoms, and if
the clinical probability of finding right ventricular over-
load by echocardiography was high, as indicated by one
of the following symptoms or signs: (near) collapse, sys-
tolic blood pressure <100 mmHg, diastolic blood pres-
sure <60 mmHg, pulse rate >100 beats/min, elevated
jugular venous pressure, electrocardiographic abnormal-
ities (pulmonary P-waves, S1Q3-complex, right bundle
branch block, T-wave inversions in precordial leads),
tachypnea (breathing frequency >20/min), PaO2
<80 mmHg (with oxygen supplementation of 2 liters),
peripheral oxygen saturation (SaO2) <95% or dyspnea
[2,3].
After informed consent was obtained, patients were
screened by transthoracic echocardiography for signs of
pulmonary hypertension. If acute right ventricle dilata-
tion was present (right ventricular end-diastolic diameter
(RVED) >30 mm [2,18] in the absence of substantial right
ventricular hypertrophy (free wall thickness <7 mm)) or
if systolic pulmonary hypertension (systolic PAP
>40 mmHg) was present, patients were included in the
study. During echocardiography all patients received 2
liters of oxygen supplementation. Patients were excluded
i ft h e yr e f u s e do rw e r eu n a b l et og i v ei n f o r m e dc o n s e n t ,
or if one of the following was present: age <18 years,
pregnancy, body mass index >35 kg/m
2, circulatory
shock (blood pressure <80/45 mmHg), mechanical venti-
lation, treatment with thrombolytic therapy, placement
of a vena cava filter, atrial fibrillation or severe pre-exis-
tent cardiopulmonary disease (heart failure, obstructive
pulmonary disease, emphysema).
The study protocol was approved by the local ethics
committee (METc), and written informed consent was
obtained from each patient prior to study entry.
Study design
Patients were randomized to receive intravenous epo-
prostenol sodium (Flolan®; GSK; Zeist, the Netherlands)
or saline placebo infusion. Infusion of epoprostenol was
started in a dose of 1 ng/kg/min. Every 10 minutes the
dose was increased with 1 ng/kg/min to a maximum
d o s eo f4n g / k g / m i n .P a t i e nts not randomised to epo-
prostenol received a similar syringe pump containing
isotonic saline. During titration of epoprostenol infusion,
blood pressure, pulse rate and peripheral oxygen satura-
tion were measured at 5 minute intervals. If, during
titration, mean blood pressure dropped by >10 mmHg,
the dose of epoprostenol was not further increased and
0.5 liter of extra sodium chloride was administrated in
30 minutes. If blood pressure dropped by >15 mmHg or
if oxygen saturation dropped by >7% (or absolute <85%)
epoprostenol infusion was decreased to the previous
titrated dose. If blood pressure and/or oxygen saturation
were not restored by down-titration, epoprostenol infu-
sion was stopped. After inclusion of the first 8 subjects,
no side effects of epoprostenol treatment at a dose of
4 ng/kg/min were observed. Because our study is a
proof-of-principle study we decided to increase epopros-
tenol infusion rate every 10 minutes with 1 ng/kg/min
to the maximum dose of 8 ng/kg/min, which is substan-
tially higher than maximum initial doses used in epo-
prostenol intervention trials in patients with chronic
pulmonary hypertension [19]. After reaching the
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were assessed hourly for the entire duration of epopros-
tenol or placebo infusion. Epoprostenol infusion was
continued for 20 hours, then tapered gradually during 4
hours and stopped. Hence, total treatment with epo-
prostenol or placebo encompassed a period of 24 hours.
The patient, the technician performing the echocar-
diographic examinations, as well as the cardiologist
assessing the echocardiographic recordings were blinded
for treatment allocation. The physician providing clini-
cal care and monitoring vital parameters was not
blinded in order to be able to respond appropriately if
the patient showed signs of hemodynamic or respiratory
deterioration.
All patients were treated with low-molecular-weight
heparin adjusted for body weight, acenocoumarol, sup-
plemental oxygen (2 l/min) and a isotonic saline infu-
sion (80 ml/hr).
Study Evaluations
At baseline, after 2.5, 24 and 72 hours echocardio-
graphic parameters were obtained. At baseline, after 4,
24 and 72 hours serum creatine kinase, cardiac troponin
T and NT-proBNP were measured. At baseline, after 4
and 24 hours, arterial blood gas analysis was performed
to detect hypoxemia or a rise in PaCO2 as a sign of
intrapulmonary shunting due to epoprostenol infusion.
The primary end point was the change in RVED
between baseline measurement and during treatment
(i.e. measurements 2 and 3). Secondary end points were
right ventricular diameter 48 hours after treatment was
stopped (i.e. measurement 4), systolic PAP, tricuspid
annular plane systolic excursion (TAPSE), right ventri-
cular fractional area change (RVFAC), serum cardiac
troponin T and NT-proBNP.
Echocardiographic Studies
Standard two-dimensional and Doppler echocardiogra-
phy was performed with a commercially available Vivid
7 system (GE medical systems; Horten, Norway) using
a 3.0 Mhz broadband (M3S) transducer; serial echocar-
diograms were analysed off-line. All examinations
included standard parasternal, apical and subcostal
views and were stored digitally for subsequent analysis.
Right ventricular function was assessed by TAPSE and
RVFAC, right ventricular dimensions by long axis and
tricuspid annular size from the apical 4 chamber view.
Furthermore, estimation of systolic PAP was obtained
by peak tricuspid regurgitant jet with continuous wave
Doppler and adding the right atrial pressure derived
from the collapse index of the inferior vena cava [20].
Cardiac output (left ventricular outflow traject) was
measured with pulse-doppler. The two-dimensional
echocardiograms were interpreted by two experienced
echocardiographers.
Laboratory Studies
NT-proBNP concentrations were determined with an
immunoradiometric assay kit (Roche diagnostics, mod-
ule E170; Mannheim, Germany). Normal values are
depending on age and gender, but in general a NT-
proBNP <200 pg/ml is considered normal. Cardiac
troponin T concentrations were determined using a
microparticle enzyme immunoassay (Roche Diagnostics,
Module E170; Mannheim, Germany). A normal value
was considered a troponin T <0.04 ng/ml.
Statistical Analyses
All analyses were performed using the SPSS statistical
software package (version 15; SPSS; Chicago, IL). Data
are shown as mean ± SD or median (range). Biochem-
ical parameters were log-transformed before analysis.
The Student-t test was used to compare RV parameters
between treatment arms and to compare relative change
of RVED compared to baseline between treatment arms.
Students-t test was chosen primarily to calculate confi-
dence intervals which may be appropriate for power
analysis for future studies. Moreover, due to small sam-
ple sizes and non-normal distributions of biochemical
parameters, also a nonparametric test (Mann-Whitney
U) was performed.
Differences were considered significant at p < 0.05.
This study was intended as a safety and proof-of-con-
cept study. In addition, obtaining point estimates of
effect-size of epoprostenol on primary endpoints may be
of use for the design of future studies. Hence, the study
is designed as a pilot study, and does not include a for-
mal power analysis based on clinically relevant effect
sizes.
Results
Subjects
Eighty two patients were screened and 14 patients were
randomized to either epoprostenol (n = 7) or placebo
(n = 7; Figure 1). The baseline characteristics of the
treatment groups were similar, as shown in Table 1. In
both groups treatment was started on average 14 hours
after the onset or progression of symptoms. All active
treatment patients received at least 4 ng/kg/min of epo-
prostenol. The 3 patients who were treated with increas-
ing dose received 8.0, 8.0 and 5.6 ng/kg/min
epoprostenol respectively. The dose in the last patient
could not be raised due to facial flushing and headache.
In two patients in the placebo group, the measurements
at 72 hours, including echocardiography, could not be
performed because of logistical reasons.
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At baseline, the mean RVED was similar in both treatment
groups (4.10 ± 0.83 cm in the epoprostenol arm and 4.13 ±
0.84 cm in the placebo arm). Epoprostenol did not have a
significant effect on RVED after 2.5 and 24 hours (Figure
2). After 2.5 hours, the relative change in RVED compared
to baseline was similar in both treatment groups, +4.2% in
the placebo arm and +6.1% in the epoprostenol arm (dif-
ference in change compared to baseline +1.9% (95% confi-
dence interval, -5.8 to 9.6, P = 0.60). After 24 hours, RVED
had increased by 2.4% in the placebo arm and had
decreased by 5.6% in the epoprostenol arm (difference in
change compared to baseline -8.0% (95% confidence inter-
val, -21.2 to 5.2, P = 0.21)). Results were similar for the 3
patients in whom epoprostenol was titrated to a mean
dose of 7.2 ng/kg/min (data not shown).
Figure 1 Patient flow.
Table 1 Characteristics of Subjects at enrollment*
Characteristics Placebo
(n = 7)
Epoprostenol
(n = 7)
Male gender 4 (57) 4 (57)
Age, yr 54.4 (19.9) 55.3 (18.2)
Weight, kg 78.9 (11.2) 74.0 (9.7)
RVED, cm 4.1 (0.84) 4.1 (0.83)
Systolic PAP, mmHg 47 (10.6) 57 (13.9)
Right ventricle free wall diameter,
mm
6.1 (0.7) 5.9 (0.9)
NT-proBNP, pg/ml 1467 (39-8549) 3885 (270-12339)
Troponin T, ng/ml 0.01 (0.01-0.13) 0.03 (0.01-0.12)
PaO2, mmHg 85 (14) 74 (12)
Definition of abbreviations: PAP = pulmonary artery pressure; RVED = right
ventricular end-diastolic diameter; PaO2 = partial arterial oxygen pressure
*Data are presented as No. (%) or mean (SD). NT-proBNP and troponin T are
presented as median (range)
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Measurements of systolic PAP, TAPSE, RVFAC, end-
diastolic right atrial diameter, end-diastolic right/left
ventricular ratio and biochemical parameters of right
ventricular overload are presented in Table 2. All echo-
cardiographic parameters of right ventricular function
remained stable during follow up. Biochemical parama-
ters improved in both groups. At no time point, signifi-
cant differences of echocardiographic and biochemical
parameters between treatment groups were observed
(P > 0.20). Systolic PAP at baseline and follow up for
both treatment groups is presented in Figure 3.
Adverse events
T h e r ew e r en os e r i o u sa d v e r s ee v e n t si ne i t h e rt r e a t -
ment arm. Two patients showed facial flushing during
infusion with epoprostenol, however, this was transient
and did not influence infusion rate. As described above,
in one patient administraton of epoprostenol could not
be increased to a maximum 8 ng/kg/min because of
persistent facial flushing and headache. Symptoms disap-
peared after gradual lowering of the infusion rate. Para-
meters of pulmonary gas exchange (PaO2,P a C O 2 or
SaO2) were similar at baseline and did not significantly
change during treatment (data not shown). There were
no blood pressure changes necessitating fluid resuscita-
tion or lowering of the epoprostenol infusion rate.
Discussion
This is the first study to investigate the effect of a vaso-
dilator for treatment of acute pulmonary embolism in a
randomized controlled trial. Our study suggests that
adding epoprostenol for 24 hours to standard treatment
of acute pulmonary embolism in patients with right ven-
tricular dilatation does not result in a significant change
in right ventricular overload.
Clearly, the sample size is too small to detect relatively
small effects of epoprostenol. However, it should be
emphasized that the point estimate of any treatment effect
of epoprostenol on right ventricular diameter and function
is very small: after 2.5 hours 2% in favour of placebo, after
24 hours 8% in favour of epoprostenol. These small
changes are not likely to be clinically relevant. Estimation
of relevant degrees of RVED or PAP reduction can possi-
bly be derived indirectly from human thrombolysis studies,
since thrombolytic treatment was associated with reduced
mortality (4.7% vs 11.1%) in the setting of right ventricular
dilatation in acute pulmonary embolism [21]. Three stu-
dies reported data on RVED after thrombolytic treatment.
These studies demonstrated reductions in right ventricular
dimensions ranging from 15% to 49% within 24 hours
[22-24]. Combining these results, a decrease in RVED of
at least 15% might be the best possible estimation of clini-
cal relevant reduction in RVED. This is twice the maximal
observed effect we found in our pilot study. A post-hoc
Figure 2 Mean (± SD) right ventricular end-diastolic diameter (RVED) for both treatment groups at baseline, 2.5 and 24 hours after
initiation of treatment and 48 hours after treatment was stopped (measurement 1, 2, 3 and 4, respectively).
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80% power to detect a difference in RVED between treat-
ment arms as large as 16%. Furthermore, it would require
55 subjects to confirm an 8% difference in treatment effect
with a study of sufficient statistical power (80%). In con-
sidering such a trial, however, one would need to weigh
the objective of demonstrating only a potential modest
benefit in mortality reduction against the potential safety
concerns and the costs of epoprostenol treatment.
Why doesn’t epoprostenol have a more pronounced
effect? In animal models of acute pulmonary embolism,
treatment with different vasodilators, including prosta-
cyclin, was associated with a more pronounced
decrease in mean PAP of 12-33% [14,25-27]. However,
the administration of vasodilating agents in these
experiments was started immediately after or even
before the onset of acute pulmonary embolism. Since
pulmonary vasocontriction is an early and partially
transient phenomenon in acute pulmonary embolism
[14], this might explain why animal models show a
larger benefit of vasodilator treatment. In our pilot
study, we treated patients with epoprostenol several
hours after the onset of symptoms. The absence of a
decrease in systolic PAP in either treatment group may
indicate that patients were already past the phase of
acute pulmonary vasocontriction. Normally, it takes
time to get to the hospital, to undergo diagnosis and
echocardiography, making earlier treatment difficult to
realise in normal practice. This may also be the expla-
nation for the minimal effect of the serotonin receptor
blocker ketanserin on PAP and cardiac output in
patients with acute pulmonary embolism [28]. For
inpatients suffering from acute pulmonary embolism,
however, the situation might be different, and pulmon-
ary vasodilatory therapy may still be effective. It might
be argued that right ventricular dysfunction was not
severe enough to expect a beneficial effect of epopros-
tenol. Indeed, TAPSE was at the lower limit of normal-
ity, suggesting at most mild right ventricular
dysfunction. Pseudonormality of TAPSE can be caused
Table 2 Changes in echocardiographic parameters, blood pressure and biochemical variables associated with acute
right ventricular overload
Baseline T = 2.5 hrs T = 24 hrs T = 72 hrs
RVED (mm) Placebo 41 ± 8 43 ± 8 42 ± 7 38 ± 5
Epoprostenol 41 ± 8 43 ± 7 38 ± 6 40 ± 9
Systolic PAP (mmHg) Placebo 47 ± 11 48 ± 17 41 ± 7 46 ± 9
Epoprostenol 57 ± 14 50 ± 19 55 ± 22 50 ± 14
TAPSE (cm) Placebo 2.0 ± 0.5 2.1 ± 0.6 2.3 ± 0.3 2.2 ± 0.6
Epoprostenol 1.9 ± 0.6 1.9 ± 0.5 2.0 ± 0.6 2.0 ± 0.5
RVFAC (%) Placebo 24 ± 18 28 ± 21 25 ± 17 29 ± 16
Epoprostenol 34 ± 24 34 ± 10 35 ± 16 33 ± 10
RAD (cm) Placebo 4.7 ± 0.7 4.4 ± 0.8 4.7 ± 1.3 4.3 ± 0.9
Epoprostenol 4.2 ± 0.9 4.6 ± 1.0 4.1 ± 1.2 4.1 ± 1.0
RV/LV Placebo 0.82 ± 0.16 0.88 ± 0.10 0.89 ± 0.15 0.69 ± 0.07
Epoprostenol 0.87 ± 0.24 0.97 ± 0.14 0.77 ± 0.23 0.79 ± 0.15
ABPs (mmHg) Placebo 117 ± 6 114 ± 12 118 ± 19 124 ± 11
Epoprostenol 125 ± 27 123 ± 26 118 ± 18 134 ± 29
ABPd (mmHg) Placebo 70 ± 10 71 ± 6 72 ± 12 74 ± 11
Epoprostenol 66 ± 14 70 ± 12 71 ± 11 72 ± 11
ABPm (mmHg) Placebo 86 ± 10 86 ± 7 87 ± 11 91 ± 10
Epoprostenol 82 ± 15 88 ± 6 87 ± 12 93 ± 12
CO (l/min) Placebo 6.2 ± 1.7 6.5 ± 0.6 6.7 ± 1.2 5.4 ± 1.2
Epoprostenol 5.5 ± 1.2 6.4 ± 1.1 5.9 ± 0.8 6.0 ± 0.8
NT-proBNP (pg/ml) Placebo 1467 (39-8549) 925 (33-8322) 694 (84-6954) 343 (130-7240)
Epoprostenol 3885 (270-12339) 3043 (352-4811) 3089 (415-4892) 614 (147-4268)
Troponin T (ng/ml) Placebo 0.01 (0.01-0.09) 0.01 (0.01-0.09) 0.01 (0.01-0.07) 0.01 (0.01-0.04)
Epoprostenol 0.03 (0.01-0.13) 0.02 (0.01-0.12) 0.01 (0.01-0.07) 0.01 (0.01-0.08)
Definition of abbreviations: PAP = pulmonary artery pressure; TAPSE = tricuspid annular plane systolic excursion; RVFAC = right ventricular fractional area change;
RAD = right atrial end-diastolic diameter; RV/LV = right/left ventricular end-diastolic diameter; ABPs = systolic arterial blood pressure; ABPd = diastolic arterial
blood pressure; ABPm = mean arterial blood pressure; RVED = right ventricular end-diastolic diameter;
Values are given as the mean ± SD. NT-proBNP and troponin T are given as median (range).
At no time point significant differences of these parameters between treatment groups were observed (P > 0.20). Data for NT-proBNP and Troponin T were
log-transformed for statistical testing.
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the case in our patients. RVFAC, however, another
indicator of right ventricular function, was diminished
suggesting at least moderate dysfunction. It is intri-
guing why TAPSE and RVFAC seem discongruent in
our patients. These parameters usually correlate well,
although TAPSE can be normal in patients with a low
RVFAC [29]. It is, however, possible that a pulmonary
vasodilator would have a more pronounced effect in
patients with more severe right ventricular dysfunction.
The choice for intravenous epoprostenol as a vasodila-
tor merits discussion. Firstly, it could be argued that
intravenous administration of epoprostenol might cause
nonselective vasodilation which could lead to intrapul-
monary shunting and systemic hypotension. However,
hypotension or a decrease in PO2 (data not shown) did
not occur in the patients who received epoprostenol
infusion in our study. Inhalation of prostacyclin or nitric
oxide is more selective for pulmonary vasculature and
has shown to decrease pulmonary artery pressure in
case reports of acute pulmonary embolism [30,31].
However, inhalation of prostacyclin might increase dead
space, possibly due to mucosal swelling [32] and inhala-
tion of nitric oxide is difficult to implement in patients
who are not on mechanical ventilation. Secondly, it has
been suggested that intravenous administration of epo-
prostenol in pigs was associated with reduced right
ventricular contractility [33], yet a recent study could
not detect a change in measures of right ventricular
contractility [34]. In humans with chronic pulmonary
hypertension, epoprostenol was associated with
unchanged right ventricular dimensions or even
increased cardiac output [35,36]. The effect of epopros-
tenol on right ventricular function in acute pulmonary
hypertension is not well known. Thirdly, it is possible
that the dose of epoprostenol was not sufficient to
decrease PAP. One might argue that uptitrating iv epo-
prostenol until systemic side effects like arterial hypo-
tension occur, would be more likely to reveal beneficial
effects on right ventricular overload and pulmonary
pressures. However, increasing the dose of epoprostenol
to 7.2 ng/kg/min, which is generally considered as high-
dose, in 3 patients did not result in reduction in RVED.
We did not further increase epoprostenol infusion rate
because higher doses are usually associated with intoler-
able side-effects [37]. Finally, it is also important to
point out that other pulmonary vasodilators have differ-
ent pharmacological properties, and our findings thus
cannot be extrapolated to these alternatives.
Conclusions
This small randomized controlled trial investigated the
effect of epoprostenol in patients with acute pulmonary
embolism and right ventricular dilatation. In contrast to
Figure 3 Mean (± SD) systolic PAP for both treatment groups at baseline, 2.5 and 24 hours after initiation of treatment and 48 hours
after treatment was stopped (measurement 1, 2, 3 and 4 respectively).
Kooter et al. BMC Pulmonary Medicine 2010, 10:18
http://www.biomedcentral.com/1471-2466/10/18
Page 7 of 9the results of several case reports and studies in animals,
treatment with epoprostenol in humans did not improve
right ventricular dilatation or any other measured vari-
ables of right ventricular overload.
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